Wagih A. El-Shouny, Samoil T. Melek & Mostafa A. Sharafeldin
This study aimed to evaluate the effect of hepatic therapy combination (interferon, sovaldi & ribavirin) on type 4 hepatitis C viral strain by comparing the results of liver function tests before and after treatment. The levels of serum Interleukin 10 (IL.10) which is an important cytokine with an anti-immune, anti-inflammatory and antifibrotic function (Grove et al., 2000) also was measured for all subjects to give an indication of liver inflammation. The statistical analyses of liver functions were varied among the tested cases. The investigated cases included 40 patient and 10 healthy individuals as control group. The individuals of this study were classified into 3main groups, Control group: 10 individuals looks like healthy, free from diseases and not taken medications with negative PCR results, Group No. 1:40 hepatic patients (chronically infected) with positive HCV-PCR results and Group No. 2: 40 chronic hepatic patients treated by hepatic therapy (interferon, sovaldi & ribavirin).The results of PCR analysis of group No.2 (after the end of treatment course) became negative in all members where all members of group No.1 were positive PCR. The statistical analysis of liver functions showed that there were no significant differences between group No.1 and group No.2 in the results of S.G.P.T, S.G.O.T, Albumin and alkaline Phosphatase, low significant difference between results of group No.1 and group No.2 in the analysis of total and direct bilirubin and moderate significant difference in the results of gamma glutamyl Transaminase where the results of analysis of group No.2 were relatively better than the results of group No.1. The previous results indicating that the therapy combination (interferon, sovaldi & ribavirin) has a remarkable effect on HCV genotype 4 that spread in Egypt.